(CercleFinance.com) – Bristol Myers Squibb announces that it has signed a global capacity reservation and supply agreement with Cellares for the manufacturing of CAR-T cell therapies, in a transaction valued at $380 million in upfront payments and steps.
Cellares will allocate multiple cell shuttles and its fully automated, high-throughput Cell Q systems in its smart factories in the United States, European Union and Japan for exclusive use for the benefit of Bristol Myers Squibb.
This collaboration will enable the pharmaceutical group to expand its manufacturing capabilities, meeting the growing demand for its diverse range of cellular therapies, bringing them to more patients more quickly.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
